Dynamics in Post-pandemic Global Human cytomegalovirus 65 kDa Phosphoprotein Industry: Supply and Demand, Markets and Prices 2021-2027

Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Status and Forecast (2016-2027)
  • 1.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Human cytomegalovirus 65 kDa Phosphoprotein Supply by Company

• 2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Company
• 2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Company
• 2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Company
• 2.4 Human cytomegalovirus 65 kDa Phosphoprotein Production Location and Sales Area of Main Manufacturers
• 2.5 Trend of Concentration Rate

3 Global and Regional Human cytomegalovirus 65 kDa Phosphoprotein Market Status by Category

• 3.1 Human cytomegalovirus 65 kDa Phosphoprotein Category Introduction
  • 3.1.1 HB-101
  • 3.1.2 CyMVectin
  • 3.1.3 ASP-0113
  • 3.1.4 PepVax
  • 3.1.5 Others
• 3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Market by Category
  • 3.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Category (2016-2021)
  • 3.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Category (2016-2021)
  • 3.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Category (2016-2021)
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Human cytomegalovirus 65 kDa Phosphoprotein Market Status by End User/Segment

• 4.1 Human cytomegalovirus 65 kDa Phosphoprotein Segment by End User/Segment
  • 4.1.1 Brain Tumor
  • 4.1.2 Hemotaological Tumor
  • 4.1.3 Kidney Transplant Rejection
  • 4.1.4 Liver Transplant Rejection
  • 4.1.5 Others
• 4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Market by End User/Segment
  • 4.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by End User/Segment (2016-2021)
  • 4.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by End User/Segment (2016-2021)
  • 4.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by End User/Segment (2016-2021)
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Status by Region

• 5.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market by Region
  • 5.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Region
  • 5.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Region
• 5.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Status
• 5.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Status
• 5.4 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Status
• 5.5 Central & South America Human cytomegalovirus 65 kDa Phosphoprotein Market Status
• 5.6 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Status

6 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Status

• 6.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Market by Country
  • 6.1.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Country (2016-2021)
  • 6.1.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2016-2021)
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Status

• 7.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market by Country
  • 7.1.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Country (2016-2021)
  • 7.1.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2016-2021)
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Status

• 8.1 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market by Country
  • 8.1.1 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Country (2016-2021)
  • 8.1.2 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2016-2021)
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Human cytomegalovirus 65 kDa Phosphoprotein Market Status

• 9.1 Central & South America Human cytomegalovirus 65 kDa Phosphoprotein Market by Country
  • 9.1.1 Central & South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Country (2016-2021)
  • 9.1.2 Central & South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2016-2021)
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Status

• 10.1 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Market by Country
  • 10.1.1 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Country (2016-2021)
  • 10.1.2 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2016-2021)
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Supply Chain and Manufacturing Cost Analysis

• 11.1 Supply Chain Analysis
• 11.2 Production Process Chart Analysis
• 11.3 Raw Materials and Key Suppliers Analysis
  • 11.3.1 Raw Materials Introduction
  • 11.3.2 Raw Materials Key Suppliers List
• 11.4 Human cytomegalovirus 65 kDa Phosphoprotein Manufacturing Cost Analysis
• 11.5 Human cytomegalovirus 65 kDa Phosphoprotein Sales Channel and Distributors Analysis
  • 11.5.1 Human cytomegalovirus 65 kDa Phosphoprotein Sales Channel
  • 11.5.2 Human cytomegalovirus 65 kDa Phosphoprotein Distributors
• 11.6 Human cytomegalovirus 65 kDa Phosphoprotein Downstream Major Buyers

12 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Forecast by Category and by End User/Segment

• 12.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume and Sales Value Forecast (2022-2027)
• 12.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Forecast by Category
  • 12.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Forecast by Category
  • 12.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Forecast by Category
  • 12.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price Forecast by Category
• 12.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Forecast by End User/Segment
  • 12.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Forecast by End User/Segment
  • 12.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Forecast by End User/Segment
  • 12.3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price Forecast by End User/Segment

13 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Forecast by Region/Country

• 13.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Forecast by Region (2022-2027)
  • 13.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Forecast by Region (2022-2027)
  • 13.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Vical Inc
  • 14.1.1 Company Information
  • 14.1.2 Human cytomegalovirus 65 kDa Phosphoprotein Product Introduction
  • 14.1.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 VBI Vaccines Inc
  • 14.2.1 Company Information
  • 14.2.2 Human cytomegalovirus 65 kDa Phosphoprotein Product Introduction
  • 14.2.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 Vaximm AG
  • 14.3.1 Company Information
  • 14.3.2 Human cytomegalovirus 65 kDa Phosphoprotein Product Introduction
  • 14.3.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Vakzine Projekt Management GmbH
  • 14.4.1 Company Information
  • 14.4.2 Human cytomegalovirus 65 kDa Phosphoprotein Product Introduction
  • 14.4.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 Immunomic Therapeutics Inc
  • 14.5.1 Company Information
  • 14.5.2 Human cytomegalovirus 65 kDa Phosphoprotein Product Introduction
  • 14.5.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Hookipa Biotech AG
  • 14.6.1 Company Information
  • 14.6.2 Human cytomegalovirus 65 kDa Phosphoprotein Product Introduction
  • 14.6.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Astellas Pharma Inc
  • 14.7.1 Company Information
  • 14.7.2 Human cytomegalovirus 65 kDa Phosphoprotein Product Introduction
  • 14.7.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.7.4 SWOT Analysis

...

15 Conclusion

16 Methodology